Hochberg, Marc C <br/><br/>
When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.  [electronic resource] 

 -  Arthritis & rheumatology (Hoboken, N.J.)  Feb 2016 
 - 382-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2326-5205 
<br/><br/><label>Standard No.: </label>10.1002/art.39492  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Inflammatory Agents, Non-Steroidal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Arthroplasty, Replacement--statistics & numerical data<br/>Chronic Pain--drug therapy<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Humans<br/>Low Back Pain--drug therapy<br/>Osteoarthritis--drug therapy<br/>Osteonecrosis--chemically induced<br/>Proportional Hazards Models<br/>Randomized Controlled Trials as Topic